Should intravitreal dexamethasone implant in refractory diabetic macular edema be used as an adjuvant therapy or switch therapy?
In a real-world setting, it seems more reasonable to use intravitreal dexamethasone implant as a switch therapy rather than an adjuvant therapy for diabetic macula edema refractory to ranibizumab despite three consecutive monthly injections of ranibizumab. Patients switched to intravitreal dexamethasone implant were found to have better anatomic and visual outcomes at 12 months than those who continued ranibizumab therapy despite their less-than-optimal responses.
Authors
- Özgür Artunay (ORCID: https://orcid.org/0000-0003-2002-7393)
- Gürkan Erdoğan (ORCID: https://orcid.org/0000-0003-4155-0407)
- Uğur Tunç (ORCID: https://orcid.org/0000-0002-5869-1524)
- Yusuf Berk Akbaş (ORCID: https://orcid.org/0000-0001-8613-5560)
- Semih Çakmak (ORCID: https://orcid.org/0000-0003-2638-0569)
- Gökhan Demir (ORCID: https://orcid.org/0000-0002-3293-3396)
- Abdullah Özkaya (ORCID: https://orcid.org/0000-0002-1940-8669)
- Elmas Yüksel Şükün (ORCID: https://orcid.org/0000-0003-3320-3739)
Institutions
- Memorial Sisli Hospital (TR)
Publication Details
- Journal
- Arquivos Brasileiros de Oftalmologia
- Published
- 2024-10-03
- DOI
- https://doi.org/10.5935/0004-2749.2023-0229
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00